Journal of Neural Transmission

, Volume 119, Issue 12, pp 1477–1482 | Cite as

Extracts of Sideritis scardica as triple monoamine reuptake inhibitors

  • Rainer KnörleEmail author
Basic Neurosciences, Genetics and Immunology - Original Article


Sideritis species are traditionally used within the Mediterranean area as teas, flavouring agents or for therapeutical purposes. The aim of this study was to investigate the effects of Sideritis scardica extracts on the monoamine transporters and to derive and explain possible medicinal applications from the pharmacological profile of the extracts. We have studied the effect of various S. scardica extracts on serotonin, noradrenaline and dopamine uptake in rat brain synaptosomes and serotonin uptake in human JAR cells. All extracts inhibited the uptake of all three monoamines into rat brain synaptosomes by their respective transporters, the alcoholic extracts being more effective than the water extract. EC50 values were in the range of 30–40 μg/ml. Inhibition of the human serotonin transporter by the methanol extract was even more effective (EC50 1.4 μg/ml). Combining Sideritis ethanol extract and fluvoxamine resulted in a leftward shift of the fluvoxamine concentration–response curve. The pharmacological profile of S. scardica extracts as triple monoamine reuptake inhibitors suggests their use in the phytochemical therapy of mental disorders associated with a malfunctioning monoaminergic neurotransmission, such as anxiety disorders, major depression, attention-deficit hyperactivity disorder, mental impairment or neurodegenerative diseases.


Sideritis Monoamine transporter inhibition Anxiety disorders Major depression ADHD Alzheimer’s disease 



This study was supported in part by a grant from the Bundesministerium für Wirtschaft und Technologie (ProInno II; KU 0004501 AJ4).

Conflict of interest

Based on the results presented in this paper, two European patents were granted to IBAM GbR (EP 1 634 602, EP 2 229 950). They comprise the treatment of depressive disorders, anxiety disorders and ADHD with extracts of Sideritis species.


  1. Abdülselam E, Öztürk M, Boga M, Topcu G (2009) Antioxidant and anticholinesterase activity evaluation of ent-kaurane diterpenoids from Sideritis arguta. J Nat Prod 72:500–502CrossRefGoogle Scholar
  2. Banks WA (2009) Characteristics of compounds that cross the blood–brain barrier. BMC Neurol 9(Suppl 1):S3–S7PubMedCrossRefGoogle Scholar
  3. Bergmeyer HU, Bernt E (1974) Lactate dehydrogenase. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Academic Press, New York, pp 574–579Google Scholar
  4. Bruno M, Piozzi P, Apostolides N, Arnold K, Baser HC, Tabanca N, Kirimer N (2005) Kaurane diterpenoids from three Sideritis species. Turk J Chem 29:61–64Google Scholar
  5. Charney DS (1998) Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psych 59(14):11–14Google Scholar
  6. Chen Z, Skolnick P (2007) Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 16:1365–1377PubMedCrossRefGoogle Scholar
  7. Davis PH (1982) Flora of Turkey and the east Aegean Islands, vol 7. Universtity Press, EdinburghGoogle Scholar
  8. Expert Council Natural Medicine (2004) Pascoe study 2004. Pascoe, GiessenGoogle Scholar
  9. Garcia PA, de Oliveira AB, Batista R (2007) Occurrence, biological activities and synthesis of kaurane diterpenes and their glycosides. Molecules 12:455–483PubMedCrossRefGoogle Scholar
  10. González-Burgos E, Carretero ME, Gómez-Serranillos MP (2011) Sideritis spp.: uses, chemical composition and pharmacological activities-a review. J Ethnopharmacol 135:209–225PubMedCrossRefGoogle Scholar
  11. Koleva II, Linssen JPH, von Beek TA, Evstatieva LN, Kortenska V, Handjeva N (2003) Antioxidant activity screening of extracts from Sideritis species (Labiatae) grown in Bulgaria. J Sci Food Agricult 83:809–819CrossRefGoogle Scholar
  12. Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C (2010) Quantitative pharmacology approach in Alzheimer’s disease: efficacy modelling of early clinical data to predict clinical outcome of tesofensine. The AAPS Journal 12:117–129PubMedCrossRefGoogle Scholar
  13. Marks DM, Pae CU, Patkar AA (2008) Triple reuptake inhibitors: the next generation of antidepressants. Current Neuropharm 6:338–343CrossRefGoogle Scholar
  14. Menghini L, Massarelli P, Bruni G, Menghini A (2005) Preliminary evaluation on anti-inflammatory and analgesic effects of Sideritis syriaca L. herba extracts. J Med Food 8:227–231PubMedCrossRefGoogle Scholar
  15. Nutt DJ (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psych 69 (Suppl E1):4–7Google Scholar
  16. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH (2000) Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293:870–878PubMedGoogle Scholar
  17. Sitte HH, Freissmuth M (2007) Monoamine transporters in the brain: structure and function. In: Lajta A, Reith MEA (eds) Handbook of neurochemistry and molecular neurobiology: neural membranes and transport, 3rd edn. Springer, New York, pp 339–362CrossRefGoogle Scholar
  18. Strid A (1991) Mountain flora of Greece, vol 2. University Press, EdinburghGoogle Scholar
  19. Topcu G, Gören AC, Kilic T, Yildiz YK, Tümen G (2002) Diterpenes from Sideritis sipylea and S. dichotoma. Turk J Chem 26:189–194Google Scholar
  20. Vasilopoulou GC, Kontogianni VG, Linardaki ZI, Iatrou G, Lamari FN, Nerantzaki AA, Gerothanassis IP, Tzakos AG, Margarity M (2011) Phytochemical composition of “mountain tea” from Sideritis clandestina subsp. clandestina and evaluation of its behavioral and oxidant/antioxidant effects on adult mice. Eur J Nutr. doi: 10.1007/s00394-011-0292-2 PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.IBAM GbRDenzlingenGermany

Personalised recommendations